Repligen Corporation $RGEN Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

Key Points

• BNP PARIBAS ASSET MANAGEMENT Holding S.A. has reduced its stake in Repligen Corporation by 4.1%, selling 13,353 shares, and now holds approximately 0.56% of the company valued at $40.1 million.
• Repligen reported Q2 EPS of $0.37, missing analysts' expectations by $0.03, while revenue increased by 14.8% year-over-year to $182.37 million.
• Several institutional investors have recently adjusted their holdings in Repligen, with 97.64% of the company owned by institutional investors overall.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 4.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 315,102 shares of the biotechnology company's stock after selling 13,353 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.56% of Repligen worth $40,093,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD grew its position in Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after acquiring an additional 743,815 shares during the period. Point72 Asset Management L.P. grew its position in Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after acquiring an additional 594,189 shares during the period. Alyeska Investment Group L.P. purchased a new position in Repligen in the fourth quarter worth approximately $53,428,000. Nuveen LLC purchased a new position in Repligen in the first quarter worth approximately $35,536,000. Finally, Artemis Investment Management LLP grew its position in Repligen by 110.1% in the first quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company's stock worth $41,128,000 after acquiring an additional 169,397 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Stock Down 1.6%

Shares of NASDAQ:RGEN traded down $1.94 on Wednesday, hitting $121.56. 735,985 shares of the company's stock were exchanged, compared to its average volume of 965,674. The firm's 50-day moving average is $121.95 and its 200 day moving average is $132.06. The company has a market capitalization of $6.84 billion, a PE ratio of -486.22, a P/E/G ratio of 2.27 and a beta of 1.05. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company's revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

Insider Activity

In other news, Director Martin D. Madaus bought 1,800 shares of the business's stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on RGEN. Evercore ISI lowered their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. HC Wainwright reiterated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price objective for the company in a research report on Tuesday, July 22nd. Finally, Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research report on Tuesday, April 29th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.